Pfizer starts biosimilar rituximab Phase I/II trial

May 9, 2012 9:55 AM

Pfizer Inc. has recently started the clinical trials of its biosimilar rituximab program. The Phase I/II trial will be conducted in rheumatoid arthritis patients comparing the pharmacokinetics, pharmacodynamics and safety to that of different versions of rituximab sold in the EU and US. 

The trial, REFLECTIONS B328-01, which started in March this year will be conducted globally in 210 patients with moderate to severe rheumatoid arthritis who are being treated with methotrexate. The patients will receive two intravenous treatments with either PF-05280586 or Rituxan or MabThera. Pfizer expects the study to be finished in December 2013.

Rituximab, sold under different brand names in the US and other parts of the world is a blockbuster biologic of Biogen Idec and Genentech (Roche). The product is approved to treat Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis in the EU and US, plus it is approved to treat diffuse large B cell lymphoma in the EU. Rituximab is also used for other types of lymphoma (e.g. Mantle Cell lymphoma) in certain parts of the world.

Rituximab, like many other blockbuster monoclonal antibodies, is under the attack of several biosimilar manufacturers. Celltrion of South Korea, Sandoz, the generics unit of Novartis, Teva of Israel and Merck has also started clinical trials of their own rituximab biosimilars.

Source: www.clinicaltrials.gov

2 Comments

  • Rituximab has also had good results with Chronic Fatigue Syndrome (ME/CFS) patients. http://www.plosone.org/article/info:doi/10.1371/journal.pone.0026358

    This is a new market drug companies. There are an estimated 1-4 million people with ME/CFS in the United States and 17 million people around the world. Larger Clinical trials are needed. FDA approvals for the use of this drug for ME/CFS patients would open up a new customer base.

  • Pamela Bradford

    May be willing to participate in RA study. Have had RA about 7 years. Currently on Enbrel successfully which I will likely not be able to continue because of cost.

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!